Navigation Links
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Date:5/27/2009

-Clinical study planned for relapsed / refractory acute myelogenous leukemia-

PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1338, for the treatment of patients with acute myelogenous leukemia (AML). MDX-1338 is a fully human antibody that targets CXCR4, a chemokine receptor found on the surface of many cancer cells, including certain leukemias, lymphomas and other cancers. Preclinical laboratory experiments have shown that MDX-1338 can block the growth of, and even directly kill, selected human tumor cells.

The Phase 1, open-label, multicenter, dose-escalation study of MDX-1338 as a monotherapy and in combination with chemotherapy is expected to enroll up to 34 patients with relapsed/ refractory AML. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary pharmacodynamics and efficacy of MDX-1338.

"We are pleased that MDX-1338 has progressed into the clinic, representing our eighth development candidate in oncology and further enhancing our focus on oncology/immunology therapeutic indications," said Howard H. Pien, Chairman and CEO of Medarex. "We believe that MDX-1338 could have potential activity in multiple cancers. Our first Phase 1 study will be conducted in AML and future studies are expected to target a variety of other leukemias and solid tumors and may involve monotherapy and combination therapy."

The American Cancer Society estimates that in 2008, approximately 13,290 patients in the United States will be diagnosed with AML.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, developm
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
2. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
3. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
4. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
5. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
6. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
7. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
8. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
9. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
10. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... reports 90 percent radiation reduction in cardiac...wire/ -- Dr. James Earls, a radiologist from Fairf..., D.C. will present the findings of a study that s...tion heart patients received from CT scans compare...rls will present the study to the annual meeting o...
(Date:12/1/2009)...AN, Ga., Dec. 1 CeloNova BioScienc...ts for medical devices and of specialty implants, ... FSCAI, founder and medical director of Baptist Ca...will discuss the CATANIA(TM) Stent System with Nan...ovascular Interventions Conference to be held at t...
(Date:12/1/2009)..., Minn., Dec. 1 MedNet Solutions, ...y specializing in clinical study management system...ustry-leading EDC/eClinical technology solution, h... Standards Consortium (CDISC) as complying with th...tification underscores MedNet,s commitment to stre...
Breaking Medicine Technology:Radiation Reduction in Heart CT Scans Reported in Study 2Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv 2MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2TeamStaff Announces Transfer to Nasdaq Capital Market 62025 1TeamStaff Announces Transfer to Nasdaq Capital Market 62025 2TeamStaff Announces Transfer to Nasdaq Capital Market 62025 3Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 1Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 1AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH Receptor Targeted Cytotoxic Conjugate AEZS 108 in Endometrial Cancer 14959 4
(Date:12/1/2009)...wire-FirstCall/ -- With employee benefit choices b...s are providing self-service decision-making tools...ng to a new survey by Watson Wyatt, a leading glob...fer these tools believe they lead employees to mak... to the survey, 45 percent of companies offered em...
(Date:12/1/2009)...PRNewswire/ -- Edifecs, Inc., the proven leader in...olutions announced an enhanced release of Edifecs ...o HIPAA 5010 migrations. XEngine Translator provid...ows generation of test data and permits two-way tr...hus addressing most requirements for organizations...
(Date:12/1/2009)...solating behaviors jump from friend to friend , ...w study suggests that lonely people attract fellow...oo. , "Loneliness can spread from person to per...," said James H. Fowler, co-author of the study pu...ersonality and Social Psychology , and professor o...
(Date:12/1/2009)...you could quit smoking while you,re still smoking?...new system for quitting is easy, painless and, mos...s your cravings and desire to smoke will completel...cember 1, 2009 -- Izabella had tried to quit count...tine, smoking at least a pack a day. , ,Nothing w...
(Date:12/1/2009)...wire-USNewswire/ -- Individuals in consumer-driven...ith traditional coverage to exhibit a number of co...ness programs, and to be more inclined to think th...ts, according to survey results released today by ...e (EBRI). ,, At the same time, the fifth annua...
Breaking Medicine News(10 mins):Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 3Health News:Loneliness May Be Catching 2Health News:Loneliness May Be Catching 3Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 2Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4
...co Doctors, Hospital is a full service acute care ...ts competitor, St. Mary,s Hospital. Early in 2008,...in volume of patients hospital-wide. Meanwhile, St... the facility. Most notably, the issue began with...
...Science University and the University of Washingto...oss the Northwest, have received federal funding t...ng emerging or re-emerging infectious diseases tha... and Emerging Infectious Diseases was established ...
...ust Online, LLC has incorporated the NexCura(R) Ca....oncocentric.com , a free portal that provides in...elp oncologists make the best treatment decisions ...s Yoo, Ph.D., president and CEO of MedTrust Online...
...te Diagnostics, Pleads Guilty to Felony Misbrandin...corporated and its subsidiary, Nichols Institute D...ement with the United States to resolve criminal a... 2006, the Justice Department announced today. Th...
...estPennyStocks.com is pleased to offer its stock...ors who are interested in stocks on the move and i... following link: http://www.TopBestPennyStocks....fizer Inc. (NYSE: PFE ), Alcoa Inc. (NYSE: AA ...
...ly invasive surgical techniques -- most notably, l... most common surgical option across the United Sta...on. , A newer, third option is a hybrid -- hand-a...ectal surgical specialists at NewYork-Presbyterian...
Other Medicine News:Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 2Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 3Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 4Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 5Health News:OHSU scientists partner with others to form center aimed at combating infectious diseases 2Health News:OHSU scientists partner with others to form center aimed at combating infectious diseases 3Health News:MedTrust Online to Provide NexCura Cancer Profiler Tools from Thomson Reuters to Oncologists 2Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 2Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 3Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 4Health News:TopBestPennyStocks.com Issues Technical Trade Alerts on Hot Stocks in the Market Today: CAST, VM, NFLX, PFE, AA, & COF 2Health News:Helping hand of hybrid surgery benefits colorectal patients 2
Sm/RNP Anti-Extractable Nuclear Antigen (ENA) Antibodies Kit
...Zeus Scientific, Inc. ENA Screen ELISA test system...ct antibodies to extractable nuclear antigens (ant...the directional insert, this test system is capabl...such as those against Jo-1, Sm, Sm/RNP, SSA, SSB, ...
...RELISA ENA assays were designed with the proper se... the diagnosis of autoimmune disease. Sera from ov... normal individuals were tested during the develop...s compared the results to reference methods such a...
SCANLISA Anti-C1q-IgG CIC Assay
Medicine Products: